In a single-centre pilot study conducted in Cameroon, researchers found that persistent low-level viraemia accounted for approximately three-quarters of detectable viral load cases among adults receiving dolutegravir-based antiretroviral therapy. While Cameroon reports that 95.0% of individuals receiving treatment achieve viral suppression, five percent continue to present with detectable viral loads. The retrospective investigation sought to determine whether this residual detectable fraction represents persistent low-level viraemia or frank antiretroviral treatment failure.
The cohort study evaluated participants managed at the Day Hospital of Yaoundé Central Hospital between 2019 and 2024. Eligible individuals were aged 16 years and older, had been maintained on antiretroviral therapy for at least 15 months, and had undergone at least two consecutive viral load measurements during the study period. Within this protocol, persistent low-level viraemia was formally defined as two consecutive viral load measurements ranging between 50 and 999 copies per millilitre, recorded at least 10 months apart.
To evaluate treatment compliance and patient characteristics, the investigative team gathered adherence metrics directly from pharmacy refill records. Across the overall evaluated cohort of 458 participants, 27 individuals met the criteria for persistent low-level viraemia. This yielded an observed prevalence of 5.89% within the cohort, with a 95% confidence interval spanning from 4.08% to 8.44%.
Among the 36 participants in the cohort who displayed detectable viraemia, persistent low-level viraemia comprised 27 cases, representing approximately three-quarters of that subpopulation with a 95% confidence interval of 58.9% to 86.3%. The investigators noted that this particular proportion is derived from a small number of participants, which is reflected in the wide confidence interval surrounding the estimate.
Multivariable statistical analysis using Firth’s penalised likelihood logistic regression identified several independent factors associated with persistent low-level viraemia, with all reporting based on Wald confidence intervals. Poor adherence significantly increased the likelihood of the condition, presenting an adjusted odds ratio of 3.82 and a 95% confidence interval between 1.45 and 10.06. The presence of comorbidity was also identified as an independent predictor, yielding an adjusted odds ratio of 3.30 with a 95% confidence interval from 1.18 to 9.20.
A baseline viral load exceeding 100,000 copies per millilitre served as a strong independent predictor of persistent low-level viraemia, demonstrating an adjusted odds ratio of 7.01 and a 95% confidence interval extending from 1.55 to 31.68. Conversely, employment was observed to be protective against the condition, associated with an adjusted odds ratio of 0.19 and a 95% confidence interval spanning 0.06 to 0.60.
The study authors concluded that detectable viraemia within this pilot cohort was predominantly driven by persistent low-level viraemia rather than treatment failure. They highlighted adherence support, integrated clinical management of comorbidities, and attention to social vulnerability as key areas for response. Because the findings were generated within a single-centre pilot setting, the researchers emphasised that the conclusions are hypothesis-generating and require confirmation in larger, multicentre, representative cohorts prior to any broader programmatic extrapolation.
Subject of Research: Persistent low-level viraemia in adults on dolutegravir-based antiretroviral therapy in Cameroon
Article Title: The hidden 5% beyond the third 95: persistent low-level viraemia dominates detectable viraemia among adults on dolutegravir-based ART in Cameroon
Article References: Bekolo, C. E., Mbawala, A. C. T., & Kouanfack, C. (2026). The hidden 5% beyond the third 95: persistent low-level viraemia dominates detectable viraemia among adults on dolutegravir-based ART in Cameroon. AIDS Research and Therapy. https://doi.org/10.1186/s12981-026-00976-0
Image Credits: AI Generated
DOI: 10.1186/s12981-026-00976-0
Keywords: antiretroviral therapy, persistent low-level viraemia, dolutegravir, Cameroon, Yaoundé Central Hospital, viral load, HIV viral suppression, treatment failure, adherence, pharmacy refill records, Firth penalised regression, comorbidity, baseline viral load, employment, pilot study, retrospective cohort
News Source: Kristina Jarvis. (November 20, 2026). Low-Level Viraemia Dominates Detectable Viral Loads in Cameroon Cohort Study. Scienmag.



